The SPHS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the SPHS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The SPHS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View SPHS Detailed Price Forecast - CNN Money||View SPHS Detailed Summary - Google Finance|
|View SPHS Detailed Summary - Yahoo! Finance||View SPHS Stock Research & Analysis - Zacks.com|
|View SPHS Trends & Analysis - Trade-Ideas||View SPHS Major Holders - Barrons|
|View SPHS Call Transcripts - NASDAQ||View SPHS Breaking News & Analysis - Seeking Alpha|
|View SPHS Annual Report - CompanySpotlight.com||View SPHS OTC Short Report - OTCShortReport.com|
|View SPHS Fundamentals - TradeKing||View SPHS SEC Filings - Bar Chart|
|View Historical Prices for SPHS - The WSJ||View Performance/Total Return for SPHS - Morningstar|
|View the Analyst Estimates for SPHS - MarketWatch||View the Earnings History for SPHS - CNBC|
|View the SPHS Earnings - StockMarketWatch||View SPHS Buy or Sell Recommendations - MacroAxis|
|View the SPHS Bullish Patterns - American Bulls||View SPHS Short Pain Metrics - ShortPainBot.com|
|View SPHS Stock Mentions - StockTwits||View SPHS Stock Mentions - PennyStockTweets|
|View SPHS Stock Mentions - Twitter||View SPHS Investment Forum News - Investor Hub|
|View SPHS Stock Mentions - Yahoo! Message Board||View SPHS Stock Mentions - Seeking Alpha|
|View Insider Transactions for SPHS - SECform4.com||View Insider Transactions for SPHS - Insider Cow|
|View SPHS Major Holdings Summary - CNBC||View Insider Disclosure for SPHS - OTC Markets|
|View Insider Transactions for SPHS - Yahoo! Finance||View Institutional Holdings for SPHS - NASDAQ|
|View SPHS Stock Insight & Charts - FinViz.com||View SPHS Investment Charts - StockCharts.com|
|View SPHS Stock Overview & Charts - BarChart||View SPHS User Generated Charts - Trading View|
SPHS: Interim Data Reported for P2b Study of Topsalysin in Localized Prostate Cancer
Posted on Thursday July 12, 2018
A total of 38 patients received a single administration of topsalysin to treat a clinically significant tumor, which was defined for this study as either a Gleason score of 6 (pattern 3 + 3) and greater than or equal to 6 mm maximum cancer core length (MMCL), or a Gleason score of 7 (pattern 3 + 4) and less than or equal to 10 mm MCCL. Six months following administration of topsalysin each patient received a follow-up biopsy.
Today’s Research Reports on Stocks to Watch: Spectrum Pharmaceuticals and Sophiris
Posted on Wednesday June 27, 2018
NEW YORK, NY / ACCESSWIRE / June 27, 2018 / Spectrum Pharmaceuticals saw its shares rise after a Bloomberg report revealed that the hematology and oncology company may be considering a sale. Shares of Sophiris Bio were bouncing in Tuesday trading after plummeting on Monday when Wall Street learned that a patient had died in the company’s ongoing phase 2b clinical trial for its prostate drug topsalysin. Spectrum Pharmaceuticals, Inc. shares closed up 14.59% on about 6.4 million shares traded yesterday.
Today's Research Reports on Trending Tickers: Sophiris Bio and Achaogen
Posted on Tuesday June 26, 2018
NEW YORK, NY / ACESSWIRE / June 26, 2018 / U.S. equities plunged on Monday, as indexes posted their biggest one-day decline in week, as fresh threats from President Trump added to the uncertainties of ...
Sophiris Bio shares plummet 46% on news of patient death in trial for prostate cancer drug
Posted on Monday June 25, 2018
Sophiris Bio Inc. (sphs) shares plummeted nearly 46% in premarket trade on Monday after the company said that a patient had died in the company's ongoing phase 2b clinical trial for its prostate cancer drug topsalysin. The patient death happened the same day that the patient was administered the drug for the second time, the company said.